时代天使2024年海外隐形矫治案例增长3倍;君实生物首个ADC双抗获批临床 | 医药早参

每日经济新闻
21 Mar

每经记者:林姿辰每经编辑:魏官红丨 2025年3月21日 星期五 丨NO.1 中国生物制药2024年净利润同比增加50.1%3月20日,中国生物制药发布2024年年报,公司实现营业收入288.7亿元,同比增加10.2%;实现年度盈利63.6亿元,同比增加24.9%;实现归属于母公司持有者盈利35亿元,同比增长50.1%。年报显示,2024年集团共有6个创新产品获中国国家药品监督管理局(NMPA)...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10